News

Two cases illustrate how recognizing and treating Demodex can change surgical outcomes and resolve chronic dry eye disease.

A pilot study shows that analyzing how the cornea moves under air-puff stimulation may improve early keratoconus detection.

The resubmission follows a successful appeal by the company with the Office of New Drugs (OND).

Knowing pregnancy-related risks enhances patient safety.

Therini Bio begins a phase 1b DME trial of THN391, an intravitreal antibody targeting fibrin-driven retinal inflammation.

The next-generation FSYX ocular pressure adjusting pump adds wireless connectivity to transmit patient usage data to prescribing practices.

Off-label use of laboratory-grade dye preparation found to harbor Sarocladium kiliense beyond the sterilizing capacity of standard filtration.

Learning Brazilian Portuguese boosts brain resilience and may delay dementia symptoms, but a humorous lesson highlights the realities of health care paperwork and waiting rooms.

The device, described in a new study, uses a technique called temporal interference-based transcorneal electrical stimulation, or TI-TES.

NUS researchers report that plant-based photosynthetic nanoparticles restored corneal NADPH levels and reversed damage within 5 days in preclinical dry eye.

Bausch + Lomb's PreserVision AREDS3 combines the established AREDS2 micronutrient formula with a B-vitamin complex.

Michigan pediatric ophthalmologist advances childhood glaucoma care with longer-lasting Ahmed valves, Ologen, and new clues on prematurity glaucoma.

Liliana Werner, MD, PhD, joins Douglas D. Koch, MD, for a discussion on the properties, limitations, and future of IOL materials

Transient vision loss may foreshadow stroke or heart events; study urges urgent 90-day evaluation and long-term cardiovascular monitoring.

Three cases illustrate how earlier, proactive intervention can reduce medication burden and preserve vision across a range of glaucoma severity.

Two years after LASIK, hidden corneal nerve loss and immune activation persist, with higher IL‑16 and faster T‑cell motion despite normal exams.

Swiss regulator backs tinlarebant for Stargardt as DRAGON phase 3 shows slower retinal atrophy, bringing first treatment closer to patients.

Investigators noted the patient's symptoms "reliably abated when she played the oboe or when she sang, only to return immediately after stopping.”

The app is designed to improve confidence among neurology and ophthalmology trainees.

Sunil S. Patel, MD, PhD, of the University of Texas Southwestern Medical Center, breaks down QA102's first-in-class mechanism targeting harmful gut bacteria and retinal inflammation, what the phase 2 drusen volume and GA growth rate data reveal about the therapy's potential, and what a phase 3 program must address to bring an oral AMD treatment to patients without options.

Biogen buys Apellis, taking over Syfovre for geographic atrophy—what it means for GA care, trial data, safety signals, and future formulations.

Ultra-widefield pediatric retinal scans plus adaptable AI reveal hidden eye issues during routine visits, enabling comfortable, scalable screening and earlier specialist referrals.

Danish JAMA Dermatology trials show short-term topical or oral corticosteroids don’t raise intraocular pressure, easing glaucoma worries in atopic dermatitis care.

New Turkish study links sleeve gastrectomy weight loss to clearer cornea and lens, lower eye pressure, and widened anterior chamber in 6 months.

Caveolin‑1 is a membrane-associated protein expressed in many cell types that plays a key role in modulating inflammatory signaling.

Two leading retinal specialists break down MCO-010's 3-year efficacy and safety data, the significance of contralateral eye findings, and how this gene-agnostic optogenetic approach could fill a critical gap for patients with advanced inherited retinal degeneration who have limited treatment options.

Jay Chhablani, MD, a retina specialist from UPMC Vision Institute and director of the Choroidal Analysis and Research Lab at the University of Pittsburgh, discussed recent advancements in choroidal imaging.

Uveitis expert Nisha Acharya, recipient of ARVO’s Mildred Weisenfeld Award, discusses how clinical trials and big data are reshaping treatment, vaccination, and vision outcomes.